INTRODUCTION

From December 2019, a virus, named novel coronavirus (2019-nCOV), attracting the attention of the whole world. As on June 28, 2020, 9,825,539 cases were reported across the globe, with deaths up to 495,388. COVID-19, a zoonosis virus closely related to bat SARS-like coronavirus strain, is mainly transmitted through respiratory droplets and contact, while the oral route of feces remains to be determined. Common symptoms include fever, dry cough/
expectoration, fatigue, upper respiratory congestion, ecchymosis, gastrointestinal symptoms, and myalgia/arthralgia. Most patients present mild symptoms, but it may progress to severe symptoms in some patients (especially the elderly and/or patients with comorbidity). Severe patients develop rapidly into acute respiratory failure, acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, and coagulation disorders. The prognosis of patients with severe pneumonia (SP) of COVID-19 is worse than that of patients with mild type. Early recognition of the risk factors of SP contributes to antecedent intervention, which shows crucial clinical significance for the treatment and prognosis of patients. SP associates with plenty of abnormal laboratory tests, which indicate different injuries of specific organs. Complex pathophysiology involves infection and systemic inflammatory response, causing a series of reactions such as coagulation activation, liver damage, myocardial damage, and kidney damage. Platelets play a significant role in the procedure of inflammation and coagulation, activated platelets release a great number of substances, which belong to the key factors of inflammation. Mean platelet volume (MPV) has been regarded as a surrogate marker of platelet activation. MPV was a useful prognostic indicator for critical patients. Besides, some studies have shown a negative correlation between MPV and platelet count (PC) in severe patients. It is reported that the combination of MPV and PC could be more clinically significant than MPV or PC alone. As far as we know, no published article investigated the relationship between MPV/platelet count ratio (MPR) and the prognosis of COVID-19. Our research aims to assess whether MPR is a useful predictor for the progression of COVID-19.

2 MATERIALS AND METHODS

2.1 Study participants

From January 21, 2020, to February 14, 2020, patients who suffered from COVID-19 were recruited from two hospitals in southern China. Patients who were younger than 18 or suffered from liver diseases were excluded from this study. This retrospective cohort study was approved by the Ethics Committee. Written informed consent was waived.

2.2 Definitions

COVID-19 was diagnosed and classified based on the guidance from the World Health Organization (WHO). SP of COVID-19 was defined as fever or suspected respiratory infection, plus one of the following: (a) respiratory rate >30 breaths/min, (b) severe respiratory distress, and (c) SpO2 ≤ 93% on room air.

2.3 Data collection

Epidemiological, clinical, laboratory, radiological data were collected from case report forms and electronic medical records. The information recorded included demographic data, comorbid conditions, exposure history, signs, laboratory data, chest computed tomographic (CT) scans, and treatments. Laboratory findings, Chest CT results, and treatment measures during the hospital stay were monitored. Baseline laboratory data were collected on admission to the hospital. Samples of peripheral blood were collected into tubes with ethylenediamine tetraacetic acid. Mean platelet volume and platelet distribution width were determined using an automated blood cell analyzer (XN-2000, Sysmex) within 30 minutes of sample collection. MPR was defined as mean platelet volume (fL)/platelet count (×10^9/L) * 100%. Health-care providers or responsible doctors were contacted for clarification if data were missing or not clear from records.

2.4 Follow-up

After admission, patients were re-examined for laboratory data and CT if necessary. Clinical outcomes were monitored up to February 19, 2020, the final date of follow-up. Patients were censored if they were transferred, discharged, or still hospitalized without SP until the final date of follow-up. The primary outcome of this study was the SP developed.

2.5 Statistical analysis

Patients were divided into low and high MPR group according to the optimal value of baseline MPR for predicting SP developed. Baseline data were expressed as mean ± standard deviation or median (interquartile range) for continuous data, and number (%) for categorical data. Differences between two groups were compared using Student’s t test or Mann-Whitney U test for continuous data, and chi-square test, Fisher’s exact test, or Kruskal-Wallis test for categorical data. The receiver operating characteristic (ROC) curve was performed to assess the predictive ability of baseline MPR for the incidence of SP and to acquire MPR cutoff values to maximize sensitivity and specificity. Spearman’s correlation coefficients were used to assess the relationships between MPR and other clinical variables. The generalized estimating equations were conducted to compare data from repeated measures. Kaplan-Meier method was used to estimate the incidence of SP, and differences between two groups were compared by the log-rank test. The relationships of SP developed and MPR were determined by univariate and backward stepwise multivariate Cox regression analysis. Age, sex, center, and variables with P < .1 in univariate analysis were entered into the multivariate model. In Cox models, time at risk was from study entry till SP developed, discharge, transfer, or the final date of follow-up. To reduce the influence of unbalanced distribution of confounding factors, the weighted Cox regression
analysis was used to adjust confounders through the inverse probability of treatment weighting (IPTW). The propensity score was calculated in each case by a logistic regression model including factors in the Cox model. Remaining missing data were filled using the missForest R package. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) version 25.0 software (SPSS Inc) and R software (version R-3.5.5, www.r-project.org). \( P < .05 \) were considered statistically significant.

3 | RESULTS

3.1 | Baseline characteristics

By February 14, 2020, 101 patients with confirmed COVID-19 had been admitted, of whom 16 (12.9%) were considered ineligible due to age < 18 or liver diseases. 85 patients were ultimately enrolled in this study (Figure 1). The demographics and characteristics data of two groups, categorized based on the optimal cutoff value of baseline MPR for predicting SP developed, were presented in Table 1. The median age was 43.0 (34.5, 61.5), and 44 (51.8%) were male. The median days from symptom onset to admission were 3.0 (2.0, 5.0) days. No patients had been exposed to the Wuhan seafood market but 28 (32.9%) had made short-term trips to Wuhan city before illness onset. Patients in the high MPR group showed an increased prevalence of hypertension (26.9% vs 6.8%, \( P = .030 \)), but no significant difference was observed in other comorbid conditions between two groups. Among patients with SP developed, the median days from admission to SP was 6.0 (5.0, 11.5) days. Among those discharged with mild illness, the median duration of hospital stay was 14.0 (13.0, 19.0) days. All patients were diagnosed as mild illness or pneumonia of COVID-19 on admission. During follow-up, 17 (20.0%) patients were developed to SP, with a significantly higher incidence in the high MPR group than the low MPR group (42.3% vs 10.2%, \( P = .001 \)). At the end of February 19, 2020, 64 (75.3%) patients were still hospitalized, 20 (23.5%) patients were discharged, and one patient (1.2%) died during hospitalization.

Abnormalities on chest CT were detected among 77 (90.6%) patients on admission. 8 (9.4%) had unilateral, single pneumonia, 5 (5.9%) had unilateral, multiple pneumonia, and 64 (75.3%) had bilateral, multiple pneumonia. Notably, 8 (9.4%) had no typical chest CT findings, and none of them was in the high MPR group. Patients from the high MPR group had a significantly greater proportion of bilateral, multiple pneumonia on admission (92.3% vs 67.8%, \( P = .009 \)).

Most patients received antibiotic therapy (78, 91.8%) and antiviral therapy (Arbidol + lopinavir/ritonavir (70, 82.4%); Oseltamivir/ribavirin (31, 36.5%); Interferon alpha (62, 72.9%)), while high MPR group showed more proportion of administration using oseltamivir/ribavirin (53.8% vs 28.8%, \( P = .027 \)). 38 (44.7%) patients were given corticosteroid. Gamma globulin was used in 14 (16.5%) patients, and thymosin was applied in 54 (63.5%) patients. In addition, 25 (29.4%) patients were given chloroquine, and 76 (89.4%) patients were supplied with oxygen.

There were significant differences in laboratory findings on admission between two MPR levels. Patients in high MPR group showed lower white blood cell, lymphocyte, platelet, and albumin (\( P = .021 \), \( P = 0.031 \), \( P < .001 \), and \( P = .010 \), respectively), and higher MPV, PDW, creatinine, and hs-CRP (\( P < .001 \), \( P = .004 \), \( P = .030 \), and \( P = .006 \), respectively).

3.2 | Performance of baseline MPR as a predictor of SP developed by ROC curve analysis

The area under curve (AUC) of the baseline MPR and WBC for the incidence of SP were 0.740 (95% CI, 0.614-0.867, \( P = .002 \)) and 0.527 (95% CI, 0.364-0.690, \( P = .729 \)). The cutoff values of MPR for predicting SP developed were 7.44, with a sensitivity of 64.7% and specificity of 77.9% (Figure 2).
| TABLE 1 | Baseline characteristics between two MPR levels |
|---------|-----------------------------------------------|
|         | Total (n = 85) | MPR ≤ 7.44 (n = 59) | MPR > 7.44 (n = 26) | P-value |
| No. of C1/C2 | 73/12 | 51/8 | 22/4 | NA |
| MPR (%) | 6.4 ± 2.1 | 5.2 ± 1.0 | 9.0 ± 1.6 | NA |
| Demographics | | | | |
| Age (y) | 43.0 (34.5, 61.5) | 41.0 (34.0, 58.0) | 51.0 (35.5, 68.3) | 0.064 |
| Sex (male) | 44 (51.8%) | 25 (42.4%) | 19 (73.1%) | 0.009 |
| Comorbid conditions | | | | |
| Hypertension | 11 (12.9%) | 4 (6.8%) | 7 (26.9%) | 0.030 |
| Diabetes | 2 (2.4%) | 1 (1.7%) | 1 (3.8%) | 0.521 |
| Cardiovascular disease | 2 (2.4%) | 0 (0.0%) | 2 (7.7%) | 0.091 |
| Cerebrovascular disease | 1 (1.2%) | 0 (0.0%) | 1 (3.8%) | 0.306 |
| COPD | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NA |
| Renal diseases | 1 (1.2%) | 1 (1.7%) | 0 (0.0%) | 1.000 |
| Smoke | 4 (4.7%) | 3 (5.1%) | 1 (3.8%) | 1.000 |
| Exposure history in Wuhan <2 wk | 28 (32.9%) | 20 (33.9%) | 8 (30.8%) | 0.777 |
| From symptom onset to admission (d) | 3.0 (2.0, 5.0) | 3.0 (2.0, 5.0) | 3.0 (2.0, 4.3) | 0.836 |
| Temperature (°C) | 37.2 (36.7, 37.7) | 37.2 (36.7, 37.6) | 37.2 (36.7, 37.9) | 0.560 |
| SBP (mmHg) | 126.9 ± 15.3 | 124.6 ± 14.6 | 132.2 ± 15.7 | 0.035 |
| DBP (mmHg) | 83.7 ± 9.6 | 82.1 ± 8.9 | 87.3 ± 10.2 | 0.019 |
| Treatment | | | | |
| Antibiotic therapy | 78 (91.8%) | 54 (91.5%) | 24 (92.3%) | 1.000 |
| Use of corticosteroid | 38 (44.7%) | 24 (40.7%) | 14 (53.8%) | 0.261 |
| Arbidol + lopinavir/ritonavir | 70 (82.4%) | 48 (81.4%) | 22 (84.6%) | 1.000 |
| Oseltamivir/ribavirin | 31 (36.5%) | 17 (28.8%) | 14 (53.8%) | 0.027 |
| Interferon alpha | 62 (72.9%) | 42 (71.2%) | 20 (76.9%) | 0.583 |
| Gamma globulin | 14 (16.5%) | 6 (10.2%) | 8 (30.8%) | 0.027 |
| Thymosin | 54 (63.5%) | 35 (59.3%) | 19 (73.1%) | 0.225 |
| Chloroquine | 25 (29.4%) | 18 (30.5%) | 7 (26.9%) | 0.738 |
| Oxygen therapy | 76 (89.4%) | 52 (88.1%) | 24 (92.3%) | 0.715 |
| Chest CT findings | | | | |
| Normal | 8 (9.4%) | 8 (13.6%) | 0 (0.0%) | 0.013 |
| Unilateral, single pneumonia | 8 (9.4%) | 7 (11.9%) | 1 (3.8%) | |
| Unilateral, multiple pneumonia | 5 (5.9%) | 4 (6.8%) | 1 (3.8%) | |
| Bilateral, multiple pneumonia | 64 (75.3%) | 40 (67.8%) | 24 (92.3%) | |
| Blood laboratory findings | | | | |
| WBC (10^9/L) | 5.0 ± 1.7 | 5.3 ± 1.7 | 4.4 ± 1.4 | 0.021 |
| Neutrophil (10^9/L) | 3.4 ± 1.5 | 3.6 ± 1.6 | 3.0 ± 1.2 | 0.064 |
| Lymphocyte (10^9/L) | 1.1 (0.8, 1.5) | 1.1 (0.9, 1.5) | 0.9 (0.7, 1.4) | 0.031 |
| Monocyte (10^9/L) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.2 | 0.702 |
| Hb (g/L) | 139.4 ± 17.1 | 137.3 ± 18.5 | 144.1 ± 12.6 | 0.090 |
| HCT (%) | 41.1 ± 4.0 | 40.6 ± 4.2 | 42.2 ± 3.5 | 0.108 |
| Platelet (10^9/L) | 193.2 ± 52.2 | 218.3 ± 40.4 | 136.4 ± 22.8 | <0.001 |
| MPV (FL) | 11.3 ± 1.0 | 11.0 ± 0.9 | 12.0 ± 1.1 | <0.001 |
| PDW (%) | 13.2 (12.0, 14.8) | 12.6 (11.8, 13.9) | 14.6 (13.1, 16.8) | 0.004 |
| AST (U/L) | 25.0 (18.0, 33.0) | 24.0 (18.0, 33.0) | 26.4 (22.5, 33.5) | 0.244 |
| ALT (U/L) | 18.9 (12.8, 27.6) | 18.5 (12.5, 26.4) | 21.4 (13.0, 29.3) | 0.477 |

(Continues)
3.3 | Correlations between baseline MPR and clinical variables

The correlations between baseline MPR and clinical variables were presented in Table 2 using the Spearman correlation coefficient. MPR was positively correlated with age ($r = .261, P = .016$), hypertension ($r = .239, P = .028$), cardiovascular diseases (CVD) ($r = .218, P = .045$), Hb ($r = .261, P = .016$), AST ($r = .241, P = .026$), BUN ($r = .215, P = .048$), creatinine ($r = .254, P = .019$), hs-CRP ($r = .391, P < .001$), and involvement on chest CT ($r = .238, P = .028$). Moreover, MPR was negatively correlated with female ($r = −.316, P = .003$), lymphocyte ($r = −.260, P = .016$), and albumin ($r = −.331, P = .002$).

3.4 | Dynamic profile of MPR in patients with COVID-19

To compare the dynamic changes of MPR between mild and severe patients in the early stage, the MPR data were tracked from day 0 to day 7 after admission at one-day intervals (Figure 3). At the end of February 19, 2020, data from 36 patients (19 discharged without SP and 17 patients with SP developed) were analyzed using generalized estimating equations. Compared with patients discharged without SP, patients with SP developed showed a higher MPR level at baseline ($P = .005$ vs Discharge), day 1 ($P = .015$ vs Discharge), day 2 ($P = .009$ vs Discharge), and day 3 ($P = .032$ vs Discharge) after admission. Besides, the MPR level at baseline did not change during the first week in the discharge group, but decreased significantly in the SP group on day 5 ($P = .014$ vs baseline), day 6 ($P < .001$ vs baseline), and day 7 ($P = .001$ vs baseline) after admission.

3.5 | MPR associated with SP developed

Kaplan-Meier curves for MPR level based on the optimal cutoff value were shown in Figure 4. Patients in the high MPR group had an obviously higher incidence of SP than those in the low MPR group during the course of their hospitalization (log-rank test $\chi^2 = 10.66, P = .001$).

The relationship of MPR with SP incidence with defined models (with low MPR group as the reference group) was shown in
Despite the adjustment, MPR > 7.44 was associated with a higher incidence of SP. In model 3, which was a maximally adjusted model including center, age, sex, hypertension, temperature, use of corticosteroid, gamma globulin, AST, ALT, albumin, BUN, eGFR, PCO2, PO2, adjusted HRs for developing to SP were 5.841 (95% CI, 1.566-21.791, \( P = .002 \)). The optimal cutoff value of MPR for predicting SP was 7.44% (Sensitivity = 64.7%, Specificity = 77.9%).

**DISCUSSION**

In this study, we found that even after adjusting for multiple confounding factors, the increased baseline MPR was apparently associated with the progression of COVID-19. Moreover, patients with SP...
In viral pneumonia, platelet activation may cause lung injury by stimulating the detrimental inflammatory response of respiratory regulation. Platelet activation plays a crucial role in viral pneumonia. Compared to the high MPR group, the low MPR group was more seriously related to pulmonary infection and inflammation. Our results suggested that the high MPR (45.8%) in the low MPR group. Spearman’s analysis also revealed a significant positive correlation between MPR and CRP, as well as MPR and CT involvement. Our results suggested that the high MPR was more seriously related to pulmonary infection and inflammation in patients with COVID-19.

Platelets are essential for inflammation, hemostasis, and immune regulation. Platelet activation plays a crucial role in viral pneumonia. In viral pneumonia, platelet activation may cause lung injury by stimulating the detrimental inflammatory response of respiratory tract. Activated platelets not only release inflammatory mediators but also expose surface molecules (including E-selectin and P-selectin), which affect the interaction between platelets and other cells, causing systemic inflammation and immune response. The decrease in PC is associated with poor prognosis and increased mortality in hospitalized patients. In contrast, PC elevation is bound up with a good prognosis. Besides, for pneumonia patients, thrombocytopenia is a sign of adverse prognosis in hospitalized pneumonia patients and intensive care unit (ICU) patients hospitalized with severe community-acquired pneumonia (CAP). Previous studies have revealed that the increase of MPV is relevant to the adverse prognoses of patients, such as CVD, chronic inflammatory disease, severe pneumonia, septic shock, and other diseases. In patients with severe pneumonia, the increase of MPV after admission may be able to forecast the mortality. MPV is negatively correlated with PC in severe patients, which seems to be a better indicator of platelet function, has been proposed. In many diseases, the increase of MPV is obviously associated with adverse prognoses, such as pneumonia after ischemic stroke, sepsis, critical disease, CVD, febrile epilepsy in children, and malignant tumor. Rania et al have shown that if pneumonia occurs in patients with ischemic stroke, an increase in the MPV/PC ratio could predict 30 days mortality. Our study suggested that the increase of MPV was also a predictor of poor prognosis in patients with pneumonia caused by COVID-19.

The pathophysiological mechanism of MPR in predicting the adverse prognosis of patients with COVID-19 is not clear, but it may be related to the following mechanisms. Firstly, under the condition of inflammation, platelet production will increase owing to the increased synthesis of thrombopoietin mediated by multifarious cytokines. Secondly, MPV reflects the metabolism and proliferation of megakaryocytes and platelet production in bone marrow. In the beginning, when infection occurs, the release of many inflammatory cytokines (such as interleukin-1 (IL-1), IL-3 and IL-6, and tumor necrosis factor-α (TNF-α)) increases, leading to the increase of thrombopoietin and the expression of young platelets in the blood stream, which causes the increase of MPV. Besides, after stress-induced platelet destruction, the decrease of PC further stimulates megakaryocyte to produce a large number of platelets, which also leads to an increase of MPV. Thirdly, adverse prognosis in patients with decreased PC and elevated MPV may be associated with increased risk of oxidative stress, thrombosis, and apoptosis in activated platelets.

Our research has certain limitations. Firstly, this was a single ethnic group study. Whether these findings can be applied to other ethnic groups remains to be explored. Secondly, our study sample included patients from two designated hospitals in Guangdong Province. There were no data from Hubei Province, the most serious epidemic area in China. Thirdly, owing to the retrospective nature, it is hard to define an absolute range of MPR to differentiate mild patients from severe illness. Finally, the relatively small sample size is a chief limitation of this study. Due to the small sample, it should be cautious to make a conclusion. But as we observed a significant association between MPR and the incidence of SP after using several methods to reduce probable bias and confounders, we suggested that clinicians should note the possibility of a higher

### Table 3: Relationship between MPR with SP

| MPR > 7.44 group | HR (95% CI) | P     |
|------------------|------------|-------|
| Unadjusted       | 4.517 (1.665-12.250) | .003  |
| Model 1          | 2.653 (0.930-7.566)  | .068  |
| Model 2          | 3.742 (1.278-10.960) | .016  |
| Model 3          | 5.841 (1.566-21.791) | .009  |
| IPTW             | 8.337 (4.045-17.182) | <.001 |

Note: The reference group is MPR ≤ 7.44 group. Covariates included age, sex, center, and variables with P < .1 in univariate Cox analysis.

Model 1: Center, Age, Sex.
Model 2: Model 1 covariates, hypertension, temperature, and treatment (use of corticosteroid and gamma globulin).
Model 3: Model 2 covariates and laboratory data (AST, ALT, Albumin, BUN, eGFR, PCO2, PO2).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; IPTW, inverse probability of treatment weighting; MPR, mean platelet volume to platelet count ratio; SP, severe pneumonia.
risk of poor outcomes in this situation. Further large-scale prospective studies are needed to confirm the association between MPR and COVID-19.

In conclusion, our study suggested that MPR is a useful indicator to help predict whether COVID-19 patients will progress to severe pneumonia. The early application of MPR is conducive to the hierarchical management of patients’ risks and alleviates the shortage of medical resources.

CONFLICT OF INTEREST
The authors declare that they have no financial conflicts of interest. Human and animal rights All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number 2020-hg-ks-04), and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

ACKNOWLEDGEMENTS
We are very grateful to Dr Yihao Li, Dr Liya Zhu, Dr Huaxing Huang and Dr Yueqiang Wen for helpful discussions and suggestions.

REFERENCES
1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473.
2. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488.
3. Chan J-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
5. Chan KW, Wong VT, Tang S. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;48(3):737-762.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. LANCET. 2020;395(10223):497-506.
7. Wang D, Hu BO, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
8. Nording HM, Seizer P, Langer HF. Platelets in inflammation and athereogenesis. Front Immunol. 2015;6:98.
9. Gasparyan AF, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58.
10. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871-1876.
11. Tajareramuang P, Phrommintikul A, Limskuen A, Pothisat C, Chittawatanarat K. The role of mean platelet volume as a predictor of mortality in critically ill patients: a systematic review and meta-analysis. Crit Care Res Pract. 2016;2016:1-8.
12. Shin DH, Rhee SY, Jeon HJ, Park JY, Kang SW, Oh J. An increase in mean platelet volume/platelet count ratio is associated with vascular access failure in hemodialysis patients. PloS One. 2017;12(1):e170357.
13. Zampieri FG, Ranzi OT, Sabatossi V, et al. An increase in mean platelet volume after admission is associated with higher mortality in critically ill patients. Ann Intensive Care. 2014;4:20.
14. Li J, Li Y, Sheng X, et al. Combination of mean platelet volume/platelet count ratio and the APACHE II score better predicts the short-term outcome in patients with acute kidney injury receiving continuous renal replacement therapy. Kidney Blood Press Res. 2018;43(2):479-489.
15. Martin-Garcia AC, Arachchilage DRJ, Kempny A, et al. Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome. Heart. 2018;104(1):45-50.
16. Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol. 2016;37(7):9323-9331.
17. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance; 2020. World Health Organization (WHO).
18. Peng J, Qi D, Yuan G, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study. J Clin Lab Anal. 2019:2020:e23475.
19. Lance MD, Sloep M, Henskens YM, Marcus MA. Mean platelet volume as a diagnostic marker for cardiovascular disease: drawbacks of preanalytical conditions and measuring techniques. Clin Appl Thromb Hemost. 2012;18(6):561-568.
20. Cho SY, Jeon YL, Kim W, et al. Mean platelet volume and mean platelet volume/platelet count ratio in infective endocarditis. Platelets. 2014;25(8):559-561.
21. Pulavendran S, Rudd JM, Maram P, et al. Combination therapy targeting platelet activation and virus replication protects mice against lethal influenza pneumonia. Am J Respir Cell Mol Biol. 2019;61(6):689-701.
22. Lè VB, Schneider JG, Boergeling Y, et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am J Respir Crit Care Med. 2015;191(7):804-819.
23. Shteinshneider M, Barchel D, Almoznino-Sarafian D, et al. Clinical characteristics and prognostic significance of changes in platelet count in an internal medicine ward. Eur J Intern Med. 2014;25(7):646-651.
24. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002;30(8):1765-1771.
25. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30(4):753-756.
26. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148-156.
27. Mirsaedi M, Peyrani P, Aiberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest. 2010;137(2):416-420.
28. Sezgi C, Taylan M, Kaya H, et al. Alterations in platelet count and mean platelet volume as predictors of patient outcome in the respiratory intensive care unit. Clin Respir J. 2015;9(4):403-408.
29. Colkesen Y, Mudgetts R. The role of mean platelet volume in predicting thrombotic events. Clin Chem Lab Med. 2012;50(4):631-634.
30. Yu T, Dong Y, Sun Z, Sun Z. Comparison of prognostic significance of mean platelet volume/platelet count with GRACE for long-term prognosis in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Int J Cardiol. 2017;228:335-340.
31. Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. *Platelets*. 2010;21(2):122-125.

32. Lee JH, Park M, Han S, Hwang JJ, Park SH, Park SY. An increase in mean platelet volume during admission can predict the prognoses of patients with pneumonia in the intensive care unit: a retrospective study. *PLoS One*. 2018;13(12):e208715.

33. Chen J, Li Y, Zeng Y, Tian Y, Wen Y, Wang Z. High mean platelet volume associates with in-hospital mortality in severe pneumonia patients. *Mediators Inflamm*. 2020;2020:8720535.

34. Liu Z, Li X, Zhang M, et al. The role of mean platelet volume/platelet count ratio and neutrophil to lymphocyte ratio on the risk of febrile seizure. *Sci Rep*. 2018;8(1):15123.

35. Nageeb RS, Abozaid M, Nageeb GS, Omran AA. Mean platelet volume to platelet count ratio as a laboratory indicator of mortality in pneumonia following ischemic stroke. *Egypt J Neurol Psychiatr Neurosurg*. 2018;54(1):27.

36. Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. *J Intensive Care*. 2013;1(1):9.

37. Gorelik O, Izhakian S, Barchel D, et al. Prognostic significance of platelet count changes during hospitalization for community-acquired pneumonia. *Platelets*. 2017;28(4):380-386.

38. Kim CH, Kim SJ, Lee MJ, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. *PLoS One*. 2015;10(3):e0119437.

**How to cite this article**: Zhong Q, PENG J. Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19. *J Clin Lab Anal* 2021;35:e23607. [https://doi.org/10.1002/jcla.23607](https://doi.org/10.1002/jcla.23607)